Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 13/20 | 1.00 |
| ▸ | PTGER4 | P35408 | 6/20 | 1.00 |
| ▸ | PTGER1 | P34995 | 1/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.70 |
| ▸ | FABP4 | P15090 | 2/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.38 |
| ▸ | FABP3 | P05413 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1626140 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER1PTGER3FABP4 | |
| SCHEMBL7960055 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER1PTGER3FABP4 | |
| SCHEMBL7960399 | 0.97 | PTGIR (0.94) | PTGIRPTGER4PTGER1PTGER3FABP4 | |
| SCHEMBL7961741 | 0.96 | PTGIR (0.93) | PTGIRPTGER4PTGER1PTGER3FABP4 | |
| SCHEMBL7961736 | 0.96 | PTGIR (0.93) | PTGIRPTGER4PTGER1PTGER3FABP4 | |
| SCHEMBL7949886 | 0.94 | PTGIR (0.89) | PTGIRPTGER4PTGER1PTGER3FABP4 | |
| SCHEMBL7958123 | 0.94 | PTGIR (0.89) | PTGIRPTGER4PTGER1PTGER3FABP4 | |
| SCHEMBL7959445 | 0.93 | PTGIR (0.86) | PTGIRPTGER4PTGER1PTGER3KDM4E | |
| SCHEMBL7961278 | 0.93 | PTGIR (0.86) | PTGIRPTGER4PTGER1PTGER3FABP4 | |
| SCHEMBL7961274 | 0.93 | PTGIR (0.86) | PTGIRPTGER4PTGER1PTGER3FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513027-B2 | Especially oxazole, thiazole and imidazole compounds 2-substituted with phenyl -cycloalkyl or -bicycloalkyl groups; drug screening | ASTERAND UK ACQUISITION LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-20080247954-A1 | Methods for the treatment of primary headache disorders using prostanoid EP4 receptor antagonists, and assays for agents for such treatment | PHARMAGENE LABORATORIES LIMITED (GB) | 2008-10-09 | — | — | US | disclosed |
| EP-1267867-B1 | USE OF PROSTANOID EP4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEADACHE AND ASSAYS FOR SUCH ANTAGONISTS | ASTERAND UK LTD (GB) | 2008-05-14 | — | — | EP | disclosed |
| US-20030158240-A1 | Methods for the treatment of primary headache disorders using prostanoid EP4 receptor antagonists, and assays for agents for such treatment | PHARMAGENE LABORATORIES LIMITED | 2003-08-21 | — | — | US | disclosed |
| US-6437146-B1 | MESANGIAL PROLIFERATIVE GLOMERULONEPHRITIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-20 | — | — | US | disclosed |
| EP-1115712-A1 | OXAZOLE COMPOUNDS AS PROSTAGLANDIN E2 AGONISTS OR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-07-18 | — | — | EP | disclosed |
| US-6245790-B1 | ANTIINFLAMMATORY AGENTS; GASTROINTESTINAL DISORDERS; SKN DISORDERS; BONE DISORDERS; MUSCLE RELAXANTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-12 | — | — | US | disclosed |
| WO-2000018744-A1 | OXAZOLE COMPOUNDS AS PROSTAGLANDIN E2 AGONISTS OR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-06 | — | — | WO | disclosed |
| EP-0989975-A1 | OXAZOLE COMPOUNDS USEFUL AS PGE2 AGONISTS AND ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-05 | — | — | EP | disclosed |
| WO-2000016760-A2 | NEW USE OF PROSTAGLANDIN E2 ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-30 | — | — | WO | disclosed |
| WO-1998055468-A1 | OXAZOLE COMPOUNDS USEFUL AS PGE2 AGONISTS AND ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247954-A1 | Methods for the treatment of primary headache disorders using prostanoid EP4 receptor antagonists, and assays for agents for such treatment | PTGER4, PTGER1, PTGER3 | PTGIR 6/4885PTGER4 1/4885PTGER1 2/4885 |
| US-20030158240-A1 | Methods for the treatment of primary headache disorders using prostanoid EP4 receptor antagonists, and assays for agents for such treatment | PTGER1, PTGER4, PTGER3 | PTGIR 5/4885PTGER4 2/4885PTGER1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.